The Vaccines Will Probably Work. Making The Fast Will Be the Hard Part.
November 18, 2020
(The New York Times) – Industry analysts and company executives are optimistic that hundreds of millions of doses will be made by next spring. But the companies — backed with billions of dollars in federal money — will have to overcome hurdles they’ve encountered in the early days of making vaccines. Moderna’s and Pfizer’s vaccines use new technology that has never been approved for widespread use. They are ramping up into the millions for the first time. Other challenges include promptly securing raw vaccine ingredients and mastering the art of creating consistent, high-quality batches.